VIRX — Viracta Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Viracta Therapeutics Inc Reports Quarterly Net Loss Was Approximately $17.7 Million, Or $0.47 Per Share
Viracta Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Viracta Therapeutics Appoints Mark Rothera As President And CEO
Brief: Viracta Says European Commission Grants Orphan Drug Designation For Nana-val For Treatment Of Peripheral T-Cell Lymphoma
Brief: Viracta Therapeutics Appoints Jane Chung To Its Board Of Directors
Viracta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Viracta Therapeutics Reports Q2 Loss Of 28 Cents Per Share
Viracta Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Viracta Therapeutics Provides An Update On The Phase 1B/2 Trial Of Nana-Val In Patients With Advanced Epstein-Barr Virus-Positive (Ebv+) Solid Tumors And Announces Upcoming Poster Presentation At The Asco Annual Meeting
Brief: Viracta Therapeutics Reports First Quarter 2022 Results
Viracta Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Viracta Therapeutics Reports Q4 And Full Year 2021 Financial Results
Brief: Viracta Therapeutics Announces First Patient Dosed In Phase 1B/2 Trial Of Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors
Brief: Viracta Therapeutics To Be Added To The Nasdaq Biotechnology Index
NASDAQ RESUMED AT 11:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:30 AM
Viracta Therapeutics jumps on 'orphan' status for cancer treatment
Brief: Viracta Therapeutics Announces Orphan Drug Designation Granted By FDA For Its All-Oral Combination Of Nanatinostat And Valganciclovir (Nana-Val) For The Treatment Of Epstein Barr Virus-Positive Diffuse Large B-Cell Lymphoma
Brief: Viracta Therapeutics Reports Q3 Loss Per Share Of $0.40